ScreenerHero

CINGCingulate Inc. Common Stock

NAS · US · Healthcare · Biotechnology · cingulate.com
5.550USD+5.31%Mkt Cap: 80.71M $P/E: —

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United Sta…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap80.71M $
Enterprise Value55.40M $
Revenue (TTM)—
Gross Profit-8.52M $
Net Income (TTM)-22.45M $
Revenue/Share—
Last Price5.550 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.61
PEG—
EV/EBITDA-2.26
EV/Revenue—
P/S—
P/B15.40
EPS (TTM)-3.59
EPS (Forward)-0.95
52W Range
3.16027% of range11.89
52W High11.89 USD
52W Low3.160 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-894.81%
ROA-148.94%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-17.25M $
CapEx (TTM)162.14K $
FCF Margin—
FCF Yield-15.91%
Net Debt-22.11M $
Net Debt/EBITDA0.90
Balance Sheet
Debt/Equity3.50
Current Ratio3.50
Quick Ratio3.30
Book Value/Sh0.3460 USD
Cash/Share1.953 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateAug 9, 2024
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)21.40 USD
Upside (mean)+285.6%
Target Range8.000 USD – 44.00 USD
$8.000+285.6% to mean$44.00
# Analysts5
Ownership
Shares Out.14.54M
Float14.18M
Insiders28.29%
Institutions12.62%
Short Interest
Short Ratio6.3d
Short % Float16.79%
Short % Out.11.65%
Shares Short1.57M
Short (prev mo.)1.38M
Technical
SMA 504.953 (+12.1%)
SMA 2005.185 (+7.0%)
Beta-0.91
S&P 52W Chg18.16%
Avg Vol (30d)171.83K
Avg Vol (10d)146.26K
Technical Indicators
RSI (14)65.9
MACD0.1327
MACD Signal0.0810
MACD Hist.+0.0517
BB Upper5.562 USD
BB Middle4.972 USD
BB Lower4.382 USD
BB Width23.73%
ATR (14)0.3070 USD
Vol Ratio (20d)1.65x